Boston Scientific posted quarterly organic top-line and adjusted bottom-line growth of 20% and 15%, respectively, fueled by 172% year-over-year growth in electrophysiology, or EP, which includes ...

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...

Abbott Laboratories, the last of the big four players in ... market value and capture more than 70% of the global atrial fibrillation market by 2028. Pulsed Field Ablation: Stunning Growth Shocks the ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

One year into the U.S. launch of pulsed field ablation systems from Boston Scientific and Medtronic ... divided between Boston Scientific (58%), Medtronic (28%), J&J (11%), and Abbott (3%). In 2026, ...

A pair of investor calls on Jan. 22 added clarity to the rapidly evolving cardiac ablation market with Abbott Laboratories and Johnson & Johnson providing updates on their pulsed field ablation ...

using three commercial contact-force sensing focal catheters with the Centauri™ System’s optimized WAVE1™ pulsed field ablation (PFA) waveform. The system, which has since received CE mark ...

In 2024, Abbott's EP business demonstrated strength thanks to its preferred mapping systems, even though it is late to market with its own pulsed field ablation technology. However, EP growth ...

Pulsed-field ablation is a new approach to treating a ... while BSX has long been a laggard in mapping (with Johnson & Johnson and Abbott enjoying much stronger share), and it’s unclear whether ...